Literature DB >> 10874910

[Cutaneous, hepatic and hematologic manifestations due to nevirapine: DRESS syndrome?].

D Sissoko1, F Ajana, X de la Tribonnière, V Baclet, Y Mouton.   

Abstract

BACKGROUND: Manifestations similar to DRESS syndrome (drug rash with eosinophilia and systemic symptoms) may be induced by nevirapine. CASE REPORTS: Three patients developed skin rash and general signs of liver dysfunction during the first 5 weeks after starting nevirapine. Laboratory tests showed elevated eosinophil counts and signs of inflammation simulating severe infection. DISCUSSION: The incidence of DRESS syndrome is probably underestimated. No standard treatment has been proposed. In our 3 patients, parenteral corticosteroid therapy was successful, leading to a rapidly favorable clinical course although liver tests took longer to return to normal.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874910

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.

Authors:  Brittany Elizabeth Yee; Nghia Hoang Nguyen; Daniel Lee
Journal:  BMJ Case Rep       Date:  2014-05-05

2.  Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.

Authors:  June M McKoy; Charles L Bennett; Marc H Scheetz; Virginia Differding; Kevin L Chandler; Kimberly K Scarsi; Paul R Yarnold; Sarah Sutton; Frank Palella; Stuart Johnson; Eniola Obadina; Dennis W Raisch; Jorge P Parada
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients.

Authors:  David Brandariz; Alex Smithson; Vanesa Anton-Vazquez
Journal:  Indian J Sex Transm Dis AIDS       Date:  2017 Jul-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.